Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials
-
Published:2024-07
Issue:
Volume:105
Page:105186
-
ISSN:2352-3964
-
Container-title:eBioMedicine
-
language:en
-
Short-container-title:eBioMedicine
Author:
Li HuiyueORCID,
Wu YunORCID,
Zou HaotianORCID,
Koner SalilORCID,
Plichta Jennifer K.,
Tolaney Sara M.,
Zhang Jian,
He You-Wen,
Wei Qingyi,
Tang Li,
Zhang Hui,
Zhang Baoshan,
Guo Yuanyuan,
Chen Xin,
Li Kan,
Lian Liyou,
Ma Fei,
Luo ShengORCID
Reference29 articles.
1. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016
2. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer;Hortobagyi;Ann Oncol,2018
3. Monarch 3: abemaciclib as initial therapy for advanced breast cancer;Goetz;J Clin Oncol,2017
4. Breast cancer, version 4.2022, NCCN clinical practice guidelines in Oncology;Gradishar;J Natl Compr Cancer Netw,2022
5. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann Oncol,2021